Delphia Therapeutics, Inc. (Delphia), announced its launch to pioneer a new area of cancer biology - activation lethality - which targets cancer's surprising vulnerability to oncogene overactivation Delphia completed a $67 million Series A financing led by premier early life sciences investors including GV (Google Ventures), Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments.